Company Encyclopedia
View More
name
TIANXIN PHARMA
603235.SH
JiangXi Tianxin Pharmaceutical Co., Ltd. produces and sells vitamins in China. The company offers products of vitamin B6, vitamin B1, Vitamin D3, pyridoxine hydrochloride CD grade, thiamine nitrate DC grade, folic acid, biotin, ascorbyl palmitate, vitamin E 500, a-acetyl-?-butyrolactone, and vitamin D3 for use as bulk pharmaceutical chemicals, API, food additives, and feed additives, as well as in other fields. JiangXi Tianxin Pharmaceutical Co., Ltd.
257.91 B
603235.SHMarket value -Rank by Market Cap -/-

Financial Score

28/12/2025 Update
B
Personal Care ProductsIndustry
Industry Ranking4/27
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE13.35%B
    • Profit Margin27.72%A
    • Gross Margin42.58%B
  • Growth ScoreB
    • Revenue YoY10.84%B
    • Net Profit YoY10.69%C
    • Total Assets YoY12.55%B
    • Net Assets YoY7.37%B
  • Cash ScoreC
    • Cash Flow Margin360.74%C
    • OCF YoY10.84%B
  • Operating ScoreC
    • Turnover0.4C
  • Debt ScoreA
    • Gearing Ratio19.36%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TIANXIN PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 460 million yuan, a year-on-year decrease of 6.91%

    According to the Zhitong Finance APP, TIANXIN PHARMA disclosed its third-quarter report for 2025. The company achieved revenue of 1.631 billion yuan in the first three quarters, a year-on-year increase of 1.08%; net profit attributable to shareholders was 460 million yuan, a year-on-year decrease of 6.91%; net profit excluding non-recurring items was 431 million yuan, a year-on-year decrease of 7.84%; basic earnings per share were 1.06 yuan

    Zhitong·
    SH
    603235
    -1.28%
    Zhitong·
    SH
    603235
    -1.28%

    TIANXIN PHARMA released its performance for the first half of the year, with a net profit attributable to the parent company of 356 million yuan, an increase of 3.14%

    According to the Zhitong Finance APP, TIANXIN PHARMA released its semi-annual report for 2025, showing an operating income of 1.122 billion yuan, a year-on-year increase of 5.23%. The net profit attributable to shareholders of the listed company was 356 million yuan, a year-on-year increase of 3.14%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 336 million yuan, a year-on-year increase of 2.15%. The basic earnings per share were 0.82 yuan

    Zhitong·
    SH
    603235
    -1.28%
    Zhitong·
    SH
    603235
    -1.28%

    TIANXIN PHARMA: Xie Tao resigns from the position of Deputy General Manager and other roles

    On August 15th, TIANXIN PHARMA announced that the company's board of directors received a written resignation letter from the company's director and deputy general manager, Xie Tao, on the same day. Due to personal reasons, Xie Tao applied to resign from the positions of director and deputy general manager, and the resignation will take effect from the date it is delivered to the board of directors. Xie Tao's departure did not cause the number of board members to fall below the legal minimum and will not affect the board's lawful and standardized operation or the company's normal business operations

    Zhitong·
    SH
    603235
    -1.28%
    Zhitong·
    SH
    603235
    -1.28%

    TIANXIN PHARMA: Shareholders commit to extend the share lock-up period by 6 months

    TIANXIN PHARMA announced that its shareholders Hou Ding Investment, Hou Sheng Investment, and Hou Tai Investment have voluntarily committed to extend the lock-up period for their shares held prior to the company's initial public offering by 6 months, until January 11, 2026. After the extension, the listing and circulation date for the restricted shares held by the aforementioned shareholders will be January 12, 2026

    Zhitong·
    SH
    603235
    -1.28%
    Zhitong·
    SH
    603235
    -1.28%

    TIANXIN PHARMA released its first-quarter performance, with a net profit attributable to the parent company of 219 million yuan, a year-on-year increase of 48.13%

    According to the Zhitong Finance APP, TIANXIN PHARMA disclosed its first-quarter report for 2025, showing that the company achieved revenue of 619 million yuan, a year-on-year increase of 25.16%; net profit attributable to the parent company was 219 million yuan, a year-on-year increase of 48.13%; and net profit excluding non-recurring gains and losses was 209 million yuan, a year-on-year increase of 53.30%. The basic earnings per share were 0.50 yuan

    Zhitong·
    SH
    603235
    -1.28%
    Zhitong·
    SH
    603235
    -1.28%
    © 2025 Longbridge｜Disclaimer